BioInvent remains focused on BI-1206, its lead FcγRIIB‑blocking antibody, and BI-1808, its anti-TNFR2 antibody,and the BI‑1607 program is currently paused BioInvent International AB ("BioInvent") ...
LUND, SE / ACCESS Newswire / November 18, 2025 / BioInvent International (STO:BINV): Most (78%) patients experienced disease control (stable disease), including heavily pretreated individuals with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback